US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
GB8912336D0
(en)
|
1989-05-30 |
1989-07-12 |
Smithkline Beckman Intercredit |
Compounds
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
CA2066898A1
(fr)
|
1991-04-29 |
1992-10-30 |
Chuan Shih |
Composes pharmaceutiques
|
SG64322A1
(en)
|
1991-05-10 |
1999-04-27 |
Rhone Poulenc Rorer Int |
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
PT669929E
(pt)
|
1992-11-13 |
2007-04-30 |
Immunex Corp |
Ligando de elk, uma citoquina
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
AU693475B2
(en)
|
1993-10-01 |
1998-07-02 |
Novartis Ag |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
EP0729471A1
(fr)
|
1993-11-19 |
1996-09-04 |
Abbott Laboratories |
Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
|
ATE191218T1
(de)
|
1993-12-17 |
2000-04-15 |
Novartis Ag |
Rapamycin-derivate als immunosuppressoren
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(fr)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Inhibiteurs de tyrosine-kinase receptrice destines a inhiber les troubles lies a la proliferation cellulaire et compositions les contenant
|
EP0756627A1
(fr)
|
1994-04-15 |
1997-02-05 |
Amgen Inc. |
Nouvelles proteines tyrosine kinases receptrices analogues a l'eph, du type hek5, hek7, hek8, hek11
|
DK0682027T3
(da)
|
1994-05-03 |
1998-05-04 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivater med antiproliferativ virkning
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
CA2216796C
(fr)
|
1995-03-30 |
2003-09-02 |
Pfizer Inc. |
Derives de quinazoline
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
JP3053222B2
(ja)
|
1995-04-20 |
2000-06-19 |
ファイザー・インコーポレーテッド |
Mmpおよびtnf抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
CA2219659C
(fr)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Derives de rapamycine
|
SK398A3
(en)
|
1995-07-06 |
1998-07-08 |
Novartis Ag |
Pyrrolopyrimidines and processes for the preparation thereof
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
ATE217873T1
(de)
|
1996-01-23 |
2002-06-15 |
Novartis Erfind Verwalt Gmbh |
Pyrrolopyrimidinen und verfahren zu deren herstellung
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
AU716383B2
(en)
|
1996-03-15 |
2000-02-24 |
Novartis Ag |
Novel N-7-heterocyclyl pyrrolo(2,3-d)pyrimidines and the use thereof
|
RO121900B1
(ro)
|
1996-04-12 |
2008-07-30 |
Warner-Lambert Company |
Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
CA2258548C
(fr)
|
1996-06-24 |
2005-07-26 |
Pfizer Inc. |
Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
|
EP0818442A3
(fr)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
|
US6258823B1
(en)
|
1996-07-12 |
2001-07-10 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EA199900021A1
(ru)
|
1996-07-13 |
1999-08-26 |
Глаксо, Груп Лимитед |
Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
|
AR007857A1
(es)
|
1996-07-13 |
1999-11-24 |
Glaxo Group Ltd |
Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
TR199900066T2
(xx)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
DE69738749D1
(de)
|
1996-08-16 |
2008-07-17 |
Schering Corp |
Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
|
WO1998007726A1
(fr)
|
1996-08-23 |
1998-02-26 |
Novartis Ag |
Pyrrolopyrimidines substituees et procede pour leur preparation
|
SK21499A3
(en)
|
1996-08-23 |
2000-05-16 |
Pfizer |
Arylsulfonylamino hydroxamic acid derivatives
|
US6251911B1
(en)
|
1996-10-02 |
2001-06-26 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
WO1998014449A1
(fr)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Derives de pyrazole condenses et procedes pour leur preparation
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
EP0837063A1
(fr)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
Dérivés de 4-aminoquinazoline
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
US6077864A
(en)
|
1997-01-06 |
2000-06-20 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
DE69817801T2
(de)
|
1997-02-03 |
2004-03-11 |
Pfizer Products Inc., Groton |
Arylsulfonylhydroxamsäurederivate
|
ATE391719T1
(de)
|
1997-02-05 |
2008-04-15 |
Warner Lambert Co |
Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
|
BR9807824A
(pt)
|
1997-02-07 |
2000-03-08 |
Pfizer |
Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
|
EP0960098A1
(fr)
|
1997-02-11 |
1999-12-01 |
Pfizer Inc. |
Derives de l'acide arylsulfonylhydroxamique
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
US6329375B1
(en)
|
1997-08-05 |
2001-12-11 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
TR200000368T2
(tr)
|
1997-08-08 |
2000-07-21 |
Pfizer Products Inc. |
Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
JP2002502607A
(ja)
|
1998-02-09 |
2002-01-29 |
ジェネンテク・インコーポレイテッド |
新規な腫瘍壊死因子レセプター相同体及びそれをコードする核酸
|
WO1999045009A1
(fr)
|
1998-03-04 |
1999-09-10 |
Bristol-Myers Squibb Company |
Inhibiteurs de la proteine tyrosine kinase, a base d'imidazopyrazine a substitution heterocyclo
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
CO5031249A1
(es)
|
1998-05-29 |
2001-04-27 |
Sugen Inc |
Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2336848A1
(fr)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Nouveaux inhibiteurs de l'angiogenese
|
EP1109555A4
(fr)
|
1998-08-31 |
2001-11-21 |
Merck & Co Inc |
Nouveaux inhibiteurs d'angiogenese
|
DE69915004T2
(de)
|
1998-11-05 |
2004-09-09 |
Pfizer Products Inc., Groton |
5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
|
ATE556713T1
(de)
|
1999-01-13 |
2012-05-15 |
Bayer Healthcare Llc |
Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
|
ATE329596T1
(de)
|
1999-03-30 |
2006-07-15 |
Novartis Pharma Gmbh |
Phthalazinderivate zur behandlung von entzündlicher erkrankungen
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
AU783960B2
(en)
|
1999-06-07 |
2006-01-05 |
Immunex Corporation |
Tek antagonists
|
IL147442A0
(en)
|
1999-07-12 |
2002-08-14 |
Genentech Inc |
Promotion or inhibition of angiogenesis and cardiovscularization by tumor necrosis factor ligand/receptor homologs
|
AU783158B2
(en)
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
MXPA02004366A
(es)
|
1999-11-05 |
2002-11-07 |
Astrazeneca Ab |
Derivados de quinazolina como inhibidores vegf.
|
ATE514676T1
(de)
|
1999-11-24 |
2011-07-15 |
Sugen Inc |
Ionisierbare indolinon derivate und deren verwendung als ptk liganden
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
AU4721901A
(en)
|
2000-02-25 |
2001-09-03 |
Immunex Corp |
Integrin antagonists
|
CN1219753C
(zh)
|
2000-07-19 |
2005-09-21 |
沃尼尔·朗伯公司 |
4-碘苯氨基苯氧肟酸的氧合酯
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
HU230574B1
(hu)
|
2000-12-21 |
2023-11-28 |
Novartis Ag |
Pirimidinamin-származékok és ezeket tartalmazó gyógyászati készítmények, mint angiogenézis modulátorok
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
US20050009849A1
(en)
|
2003-01-03 |
2005-01-13 |
Veach Darren R. |
Pyridopyrimidine kinase inhibitors
|
EP1631588A2
(fr)
|
2003-05-23 |
2006-03-08 |
Wyeth |
Ligand du gitr et molecules et anticorps lies au ligand du gitr et leurs utilisations
|
DE602004017736D1
(de)
|
2003-07-08 |
2008-12-24 |
Novartis Ag |
Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
|
WO2005007190A1
(fr)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
EP1648900A4
(fr)
|
2003-07-11 |
2010-02-10 |
Ariad Pharma Inc |
Macrocycles contenant du phosphore
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
EP1656376A1
(fr)
|
2003-08-22 |
2006-05-17 |
Avanir Pharmaceuticals |
Derives de naphtyridine substitues servant d'inhibiteurs de facteur d'inhibition de la migration des macrophages et leur utilisation pour traiter des maladies humaines
|
WO2005055808A2
(fr)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
WO2006083289A2
(fr)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
GEP20104906B
(en)
|
2004-08-26 |
2010-02-25 |
Pfizer |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
US7666901B2
(en)
|
2004-10-13 |
2010-02-23 |
Wyeth |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
ES2400689T3
(es)
|
2004-10-18 |
2013-04-11 |
Amgen, Inc |
Compuestos de tiadiazol y métodos de uso
|
DK2343320T3
(da)
|
2005-03-25 |
2018-01-29 |
Gitr Inc |
Anti-gitr-antistoffer og anvendelser deraf
|
EP3530736A3
(fr)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CA2622870A1
(fr)
|
2005-09-20 |
2007-03-29 |
Pfizer Products Inc. |
Formes de dosage et procedes de traitement utilisant un inhibiteur de la tyrosine kinase
|
KR20080091369A
(ko)
|
2006-01-18 |
2008-10-10 |
암젠 인크 |
단백질 키나제 b (pkb) 억제제로서 티아졸 화합물
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
MY180595A
(en)
|
2006-12-07 |
2020-12-03 |
Genentech Inc |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
MX2009009968A
(es)
|
2007-03-23 |
2009-10-08 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
EP2139882B1
(fr)
|
2007-03-23 |
2013-12-25 |
Amgen Inc. |
Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
|
JP2010522177A
(ja)
|
2007-03-23 |
2010-07-01 |
アムジエン・インコーポレーテツド |
複素環化合物およびその使用
|
EP2170887A2
(fr)
|
2007-06-07 |
2010-04-07 |
Amgen Inc. |
Modulateurs de la raf kinase et leurs méthodes d'utilisation
|
EP2175884B8
(fr)
|
2007-07-12 |
2017-02-22 |
GITR, Inc. |
Thérapies combinées utilisant des molécules de liaison au gitr
|
CA2693473A1
(fr)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazoles modulateurs de l'activite de pkb
|
AU2008276521B2
(en)
|
2007-07-17 |
2011-11-03 |
Amgen Inc. |
Heterocyclic modulators of PKB
|
JP5561702B2
(ja)
|
2007-08-02 |
2014-07-30 |
アムジエン・インコーポレーテツド |
Pi3キナーゼ調節剤および使用方法
|
US8247397B2
(en)
|
2007-09-12 |
2012-08-21 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
WO2009085185A1
(fr)
|
2007-12-19 |
2009-07-09 |
Amgen Inc. |
Composés condensés de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
|
PE20091268A1
(es)
|
2007-12-19 |
2009-09-19 |
Amgen Inc |
Derivados heterociclicos como inhibidores de pi3 quinasa
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
US8415376B2
(en)
|
2008-05-30 |
2013-04-09 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
CN102203258A
(zh)
|
2008-07-02 |
2011-09-28 |
新兴产品开发西雅图有限公司 |
TGF-β拮抗剂多靶点结合蛋白
|
CN102149820B
(zh)
|
2008-09-12 |
2014-07-23 |
国立大学法人三重大学 |
能够表达外源gitr配体的细胞
|
EP2387570A1
(fr)
|
2009-01-15 |
2011-11-23 |
Amgen, Inc |
Thiazoles substitués par fluoroisoquinoléine et leurs méthodes d'application
|
US20120165334A1
(en)
|
2009-02-18 |
2012-06-28 |
Amgen Inc. |
Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors
|
AU2010226490A1
(en)
|
2009-03-20 |
2011-10-06 |
Amgen Inc. |
Inhibitors of PI3 kinase
|
UY32582A
(es)
|
2009-04-28 |
2010-11-30 |
Amgen Inc |
Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
|
WO2010132598A1
(fr)
|
2009-05-13 |
2010-11-18 |
Amgen Inc. |
Composés hétéroaryle en tant qu'inhibiteurs des pikk
|
AR077267A1
(es)
|
2009-06-25 |
2011-08-17 |
Amgen Inc |
Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
|
MX2011013666A
(es)
|
2009-06-25 |
2012-03-06 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
JP2012531435A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体
|
US8765940B2
(en)
|
2009-06-25 |
2014-07-01 |
Amgen Inc. |
Heterocyclic compounds and their uses
|
LT3023438T
(lt)
|
2009-09-03 |
2020-05-11 |
Merck Sharp & Dohme Corp. |
Anti-gitr antikūnai
|
RS53807B1
(en)
|
2009-09-11 |
2015-06-30 |
Amgen Inc. |
N- (4 - ((3- (2-AMINO-4-Pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of cancer resistant ANTIMITOTIC AGENCIES
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
PT2519543T
(pt)
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
EP3354640A3
(fr)
|
2011-04-13 |
2018-10-31 |
Innovimmune Biotherapeutics, Inc. |
Facteurs d'inhibition de la migration des macrophages (mif) et leurs utilisations
|
WO2013039954A1
(fr)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anticorps anti-gitr
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
EP2882746B1
(fr)
|
2012-08-07 |
2016-12-07 |
Merck Patent GmbH |
Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
TW201524952A
(zh)
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Kras g12c之共價抑制劑
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
BR112016008016B8
(pt)
|
2013-10-10 |
2023-09-26 |
Araxes Pharma Llc |
Compostos inibidores de kras g12c, composição farmacêutica compreendendo ditos compostos, métodos para regular a atividade e para preparar uma proteína mutante kras, hras ou nras g12c, método para inibir a proliferação de uma população de células e usos terapêuticos dos ditos compostos
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
WO2016035008A1
(fr)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2016049565A1
(fr)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions et procédés pour inhiber la ras
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
EP3280708B1
(fr)
|
2015-04-10 |
2021-09-01 |
Araxes Pharma LLC |
Composés quinazolines substitués et procédés pour leur utilisation
|
MX2017013275A
(es)
|
2015-04-15 |
2018-01-26 |
Araxes Pharma Llc |
Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
|
MX2018000777A
(es)
|
2015-07-22 |
2018-03-23 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
|
WO2017058902A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
EP3356359B1
(fr)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibiteurs de protéines kras portant la mutation g12c
|
WO2017058915A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
WO2017058805A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(fr)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibiteurs de protéines kras portant la mutation g12c
|
CA3005089A1
(fr)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
Composes quinazoline substitues en position 2 comprenant un groupe heterocyclique substitue et leur methode d'utilisation
|
WO2017100546A1
(fr)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Procédés de préparation de dérivés de quinazoléine
|
CA3009393C
(fr)
|
2015-12-23 |
2023-08-22 |
Greenovation Biotech Gmbh |
Polypeptides pour l'inhibition de l'activation du complement
|
WO2017172979A1
(fr)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Composés quinazoline substitués et procédés d'utilisation
|
AU2017266911B2
(en)
*
|
2016-05-18 |
2021-09-02 |
Array Biopharma, Inc. |
KRas G12C inhibitors
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
WO2018064510A1
(fr)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibiteurs de protéines mutantes kras g12c
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
LT3558955T
(lt)
|
2016-12-22 |
2021-11-10 |
Amgen Inc. |
Benzizotiazolo, izotiazolo[3,4-b]piridazino ir ftalazino, pirido[2,3-d] piridazino ir pirido[2,3-d]pirimidino dariniai, kaip kras g12c inhibitoriai, skirti plaučių, kasos arba storosios žarnos vėžio gydymui
|
CN110382483A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的n-杂环化合物及其使用方法
|
JOP20190272A1
(ar)
*
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
TWI731264B
(zh)
|
2017-09-08 |
2021-06-21 |
美商安進公司 |
Kras g12c抑制劑以及其使用方法
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
JP7361720B2
(ja)
|
2018-05-10 |
2023-10-16 |
アムジエン・インコーポレーテツド |
がんの治療のためのkras g12c阻害剤
|
EP3802535B1
(fr)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
AU2019291099A1
(en)
|
2018-06-21 |
2021-01-07 |
Janssen Pharmaceutica Nv |
Oga inhibitor compounds
|
CA3103049A1
(fr)
|
2018-06-21 |
2019-12-26 |
Janssen Pharmaceutica Nv |
Composes inhibiteurs d'oga
|
US11528607B2
(en)
|
2018-08-13 |
2022-12-13 |
Apple Inc. |
Techniques in evolved packet core for restricted local operator services access
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
EP3883565A1
(fr)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020156285A1
(fr)
|
2019-01-29 |
2020-08-06 |
博瑞生物医药(苏州)股份有限公司 |
Composé de benzopyridone hétérocyclique et son utilisation
|
EP3738593A1
(fr)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosage d'inhibiteur de kras pour le traitement de cancers
|
CA3140394A1
(fr)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Formes a l'etat solide
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
WO2021081212A1
(fr)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|